PET-Scan in Colorectal Cancer

References

• VuiLLEZ J. Métabolisme glucidique des cellules tumorales: conséquences pour l’utilisation de radiopharmaceutiques analogues du glucose. Médecine Nucléaire-Imagerie fonctionnelle et métabolique, 1998, 22: 9–29.
   Google Scholar
• Warburg O. The metabolism of tumors. London: Arnold Constable, 1930.
   Google Scholar
• Mellanen P., Minn H., Grenman R., Harkonen P. Expression of glucose transporters in head-and-neck tumors. Int J Cancer, 1994, 56 (5): 622–9.
   Google Scholar
• Burgman P., Odonoghue J. A., Humm J. L., Ling C. C. Hypoxia-Induced increase in FDG uptake in MCF7 cells. J Nucl Med, 2001, 42 (1): 170–5.
   Google Scholar
• Kubota R., Yamada S., Kubota K., Ishiwata K., Tamahashi N., Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglu-cose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med, 1992, 33 (11): 1972–80.
   Google Scholar
• Langen K. J., Braun U., Rota Kops E., Herzog H., Kuwert T., Nebeling B. et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. JNuclMed, 1993, 34 (3): 355–9.
   Google Scholar
• Torizuka T., Fisher S. J., Brown R. S., Wahl R. L. Effect of insulin on uptake of FDG by experimental mammary carcinoma in diabetic rats. Radiology, 1998, 208 (2): 499–504.
   Google Scholar
• Lonneux M., Borbath I., Bol A., Coppens A., Sibomana M., Bausart R. et al. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction. Eur J Nucl Med, 1999, 26 (6): 591–8.
   Google Scholar
• Abdel-Nabi H., Doerr R. J., Lamonica D. M., Cronin V. R., Galantowicz P. J., Carbone G. M. et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology, 1998, 206 (3): 755–60.
   Google Scholar
• Kantorova I., Lipska L., Belohlavek O., Visokai V., Trubac M., Schneiderova M. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med, 2003, 44 (11): 1784–8.
   Google Scholar
• Agress H., Jr., Cooper B. Z. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology, 2004, 230 (2): 417–22.
   Google Scholar
• Drenth J. P., Nagengast F. M., Oyen W. J. Evaluation of (pre-)malignant colonic abnormalities: endoscopic validation of FDG-PET findings. Eur J Nucl Med, 2001, 28 (12): 1766–9.
   Google Scholar
• Calvo F. A., Domper M., Matute R., Martinez-Lazaro R., Arranz J. A., Desco M. et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys, 2004, 58 (2): 528–35.
   Google Scholar
• Amthauer H., Denecke T., Rau B., Hildebrandt B., Hunerbein M., Ruf J. et al. Response prediction by FDG-PET after neoadju-vant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging, 2004, 31 (6): 8119.
   Google Scholar
• Guillem J. G., Moore H. G., Akhurst T., Klimstra D. S., Ruo L. Mazumdar M. et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg, 2004,, 199 (1): 1–7.
   Google Scholar
• Strauss L. G., Clorius J. H., Schlag P., Lehner B., Kimmig B., Engenhart R. et al. Recurrence of colorectal tumors: PET evaluation. Radiology 1989, 170 (2): 329–32.
   Google Scholar
• Flanagan F. L., Dehdashti F., Ogunbiyi O. A., Kodner I. J., Siegel B. A. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg, 1998, 227 (3): 319–23.
   Google Scholar
• Flamen P., Hoekstra O. S., Homans F., Van Cutsem E., Maes A., Stroobants S. et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer, 2001, 37 (7): 862–9.
   Google Scholar
• Arulampalam T., Costa D., Visvikis D., Boulos P., Taylor I., Ell P. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med, 2001, 28 (12): 175865.
   Google Scholar
• Ruers T. J., Langenhoff B. S., Neeleman N., Jager G. J., Strijk S., Wobbes T. et al. Value of positron emission tomography with [F-18]fluorodeoxy glucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol, 2002, 20 (2): 388–95.
   Google Scholar
• Strasberg S. M., Dehdashti F., Siegel B. A., Drebin J. A., Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg, 2001, 233 (3): 293–9.
   Google Scholar
• Lonneux M., Reffad A. M., Detry R., Kartheuser A., Gigot J. F., Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging, 2002, 29 (7): 915–21.
   Google Scholar
• Kalff V., Hicks R. J., Ware R. E., Hogg A., Binns D., McKenzie A. F. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med, 2002, 43 (4): 492–9.
   Google Scholar
• Cohade e., Osman M., Leal J., Wahl R. L. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med, 2003, 44 (11): 1797–803.
   Google Scholar
• Even-Sapir E., Parag Y., Lerman H., Gutman M., Levine e., Rabau M. et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology, 2004, 232 (3): 815–22.
   Google Scholar